InvestorsHub Logo
Followers 1
Posts 103
Boards Moderated 0
Alias Born 03/08/2008

Re: None

Wednesday, 08/15/2018 2:32:59 PM

Wednesday, August 15, 2018 2:32:59 PM

Post# of 9
FDA has granted orphan drug designation to MeiraGTx's AAV-CNGA3 gene therapy candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene.

Achromatopsia is a genetic retinal disease that impairs a person’s sight by preventing cone photoreceptors in the eye from functioning. AAV-CNGA3 is intended to restore cone function and is delivered to the cone receptors at the back of the eye via subretinal injection.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MGTX News